Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04330170
Other study ID # 180
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 13, 2016
Est. completion date March 28, 2020

Study information

Verified date April 2020
Source Pirogov Russian National Research Medical University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

In this study a retrospective analysis of patients database was performed, who underwent treatment for deep vein thrombosis in tertiary hospital by using inferior vena cava-filters


Description:

The aim of this research was to assess the cava-filter implantation frequency in a tertiary hospital with venous thromboembolism treatment center.

A retrospective analysis of patient's database was performed, who underwent treatment in the tertiary clinic between 2016 - 2017. In total, 2399 patients with venous thromboembolism were hospitalized, 442 cava-filters were implanted (239 in 2016 and 203 in 2017), which accounted for 18.4% of patients with venous thromboembolism. Removable cava-filters models were used in most cases (98.8%). Contraindications for anticoagulation were reason for cava-filters implantation in 119 (26.9%) cases, and in 184 patients (41.6%) cava-filters were implanted due to the inefficiency of anticoagulation. 38 (8.6%) patients with deep vein thrombosis (DVT) and pulmonary embolism had pulmonary hypertension of the 2nd to 3rd degree, which caused the implantation of cava-filters .

The occlusion of the inferior vena cava and cava-filters verified in 116 (26.9%) patients after cava-filters implantation, based on repeated ultrasound. The overall mortality rate in the group of patients with venous thromboembolism was 0.25% (6 patients), 5 of them (1.1%) underwent cava-filters implantation. The cause of all lethal outcomes was the progression of the underlying disease. During the next hospitalization 29 (6.5%) of implanted filters were endovascularly removed.

There are 18.4% of patients with venous thromboembolism undergoing cava-filters implantation for various reasons in a tertiary hospital. At the same time, occlusion of the inferior vena cava and cava-filters in the early post implantation period is observed in 26.9%. However, without clear criteria for the differentiation of cava-filters embolism from its thrombosis, we cannot assess whether this was a complication, or if the cava-filters completed its task by preventing pulmonary embolism. Thus, the validity of implanting cava filters question in terms of efficiency and safety remains unanswered, which poses the task for deep study of this problem and thorough analysis of the indications for the cava-filters implantation.


Recruitment information / eligibility

Status Completed
Enrollment 2399
Est. completion date March 28, 2020
Est. primary completion date March 28, 2020
Accepts healthy volunteers No
Gender All
Age group 16 Years to 91 Years
Eligibility Inclusion Criteria:

- Anticoagulation therapy contraindicated

- Anticoagulation therapy ineffective

- High pulmonary embolism risk (floating thrombus in proximal location)

- Deep vein thrombosis/pulmonary embolism together with high pulmonary hypertension(>50 mm.Hg)

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Russian Federation The Federal Budget-Funded Institution National Medical Surgical Center named after N. I. Pirogov of the Ministry of health of the Russian Federation Moscow

Sponsors (1)

Lead Sponsor Collaborator
Pirogov Russian National Research Medical University

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants with occlusion of inferior vena cava-filter Number of participants with embolic or thrombotic occlusion of inferior vena cava-filter from date of inferior vena cava-filter implantation until the date of discharge, up to 1-2 weeks
Secondary Number of participants who have undergone cava-filter removal Number of participants , who underwent retrieving of cava-filter due to the pulmonary embolism risk regression from date of inferior vena cava-filter implantation until the date of discharge, up to 1-2 weeks
Secondary Number of participants with implanted cava filter in whom the filter remained intact Number of participants with filter implanted without the possibility of its removal due to various reasons and without its occlusion from date of inferior vena cava-filter implantation until the date of discharge, up to 1-2 weeks
See also
  Status Clinical Trial Phase
Completed NCT05083455 - Replication of the RECORD1 Anticoagulant Trial in Healthcare Claims Data
Completed NCT06009484 - VTE Incidence After Curative Colon Cancer Surgery in an ERAS Program